Does telemedicine follow-up reduce length of stay in patients with heart failure? A retrospective cohort study
Published
March 8, 2025
Paper ID
PAP-000237
Status
Published
DOI
10.65712/tmj.test000495
Advance Services
Abstract
Background: Earlier studies of telemedicine follow-up were small or single-centre. Methods: Missing data were handled with multiple imputation. Results: 3543 participants were included (median age 72 years). length of stay occurred in 8% of the intervention group versus 20% of controls. Conclusion: These findings suggest that telemedicine follow-up is associated with better length of stay in patients with heart failure.
Introduction
The cost of length of stay to health systems is substantial. Practice around telemedicine follow-up varies widely between centres. length of stay remains a leading cause of avoidable harm among patients with heart failure. Earlier studies of telemedicine follow-up were small or single-centre.
Practice around telemedicine follow-up varies widely between centres. Earlier studies of telemedicine follow-up were small or single-centre.
Practice around telemedicine follow-up varies widely between centres. Guidelines make only a weak recommendation on telemedicine follow-up. Earlier studies of telemedicine follow-up were small or single-centre.
Discussion
Future work should test telemedicine follow-up in a pragmatic multicentre trial. These findings suggest that telemedicine follow-up is associated with better length of stay in patients with heart failure. Strengths include the sample size and blinded outcome assessment.
Implementation will depend on staffing, cost and local protocols. These findings suggest that telemedicine follow-up is associated with better length of stay in patients with heart failure. Future work should test telemedicine follow-up in a pragmatic multicentre trial.
Conclusions
Telemedicine follow-up is a reasonable option for patients with heart failure to improve length of stay.
References
1. Mensah S, Larsen F, et al. Vitamin D supplementation and health-related quality of life. BMC Med. 2024;263(4):708-936.
2. Okafor P, Ibrahim Q, et al. Low-dose aspirin and acute kidney injury. BMC Med. 2023;239(7):119-1038.
3. Haddad I, Herrera K, et al. An antibiotic stewardship programme and length of stay. Pediatrics. 2016;277(11):309-1066.
4. Zhang W, Kowalski W, et al. Point-of-care ultrasound and ventilator-free days. Crit Care Med. 2020;92(11):736-1567.
5. Patel V, Tanaka O, et al. Home-based cardiac rehabilitation and health-related quality of life. Eur Heart J. 2023;89(10):241-1551.
6. Farouk S, Zhang S, et al. An enhanced recovery pathway and surgical site infection. BMC Med. 2025;163(10):157-1473.
7. Costa D, Mensah B, et al. High-flow nasal oxygen and patient satisfaction. BMJ. 2021;260(9):399-1182.
8. Rahman W, Okafor O, et al. Tranexamic acid and chronic pain scores. Eur Heart J. 2008;126(6):558-1496.
Appendices
Supplementary tables are available on request.
Materials and Methods
The primary outcome was length of stay, assessed blind to allocation.
Eligible participants were patients with heart failure. Missing data were handled with multiple imputation.
Results
The adjusted odds ratio was 0.74 (95% CI 0.34 to 0.79). Effects were consistent across prespecified subgroups.
length of stay occurred in 6% of the intervention group versus 18% of controls. Effects were consistent across prespecified subgroups. length of stay occurred in 15% of the intervention group versus 14% of controls. Serious adverse events were rare and similar between groups.
The adjusted odds ratio was 0.52 (95% CI 0.38 to 0.95). length of stay occurred in 6% of the intervention group versus 35% of controls. length of stay occurred in 21% of the intervention group versus 19% of controls.
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Centre A | 508 | 33 | 27.0 | 0.98 |
| Age ≥ 65 | 653 | 22 | 27.4 | 0.70 |
| Centre B | 724 | 109 | 20.9 | 0.70 |
| Male | 801 | 101 | 19.9 | 0.93 |
| Age ≥ 65 | 110 | 119 | 8.2 | 0.49 |
| Male | 419 | 45 | 38.7 | 0.80 |
Values are n (%) unless stated otherwise.

Shown for patients with heart failure; error bars are 95% confidence intervals.
length of stay occurred in 21% of the intervention group versus 18% of controls. Effects were consistent across prespecified subgroups.
Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.89 (95% CI 0.48 to 0.90). Effects were consistent across prespecified subgroups. 3043 participants were included (median age 74 years).